Health Care & Life Sciences » Biotechnology | Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc. | Ownership

Companies that own Corbus Pharmaceuticals Holdings Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
4,387,188
7.67%
0
0%
06/30/2018
Knoll Capital Management LP
3,913,874
6.84%
56,889
19.94%
06/30/2018
BlackRock Fund Advisors
3,711,790
6.49%
259,219
0%
06/30/2018
The Vanguard Group, Inc.
2,279,016
3.98%
206,269
0%
06/30/2018
ETF Managers Group LLC
1,830,450
3.2%
-626,471
0.47%
06/30/2018
IFP Advisors, Inc.
1,500,805
2.62%
160,250
0.35%
06/30/2018
SSgA Funds Management, Inc.
797,955
1.4%
809
0%
06/30/2018
Morgan Stanley Smith Barney LLC (Private Banking)
589,441
1.03%
104,216
0%
06/30/2018
Northern Trust Investments, Inc.
576,063
1.01%
44,094
0%
06/30/2018
Geode Capital Management LLC
493,070
0.86%
79,259
0%
06/30/2018

About Corbus Pharmaceuticals Holdings

View Profile
Address
500 River Ridge Drive
Norwood Massachusetts 02062
United States
Employees -
Website http://www.corbuspharma.com
Updated 07/08/2019
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.